Merck Completes Acquisition of Cidara Therapeutics, Expanding Respiratory Portfolio

Merck completes acquisition of Cidara Therapeutics, expanding respiratory portfolio. The acquisition strengthens Merck's business development strategy, focusing on compelling science and value. Merck acquired Cidara for $221.50 per share, with 85.96% of shares tendered. The acquisition will add CD388, a long-acting antiviral candidate, to Merck's portfolio for the prevention of symptomatic influenza in high-risk individuals.